The costs and benefits of bowel cancer service developments using discrete event simulation

Journal of the Operational Research Society

Volumn 60, Issue 10, 2009, Pages 1305-1314

  Pilgrim, H ^a,e   Tappenden, P ^a   Chilcott, J ^a   Bending, M ^b   Trueman, P ^b   Shorthouse, A ^c   Tappenden, J ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bowel cancer; Health service; Simulation

Indexed keywords

BEHAVIORAL RESEARCH; COST EFFECTIVENESS; DECISION MAKING; DIAGNOSIS; DISEASES; PATIENT TREATMENT;

BOWEL CANCER; COLORECTAL CANCER; COSTS AND BENEFITS; HEALTH SERVICES; HEALTHCARE RESOURCES; RESOURCE ALLOCATION DECISION; SERVICE DEVELOPMENT; SIMULATION;

DISCRETE EVENT SIMULATION;

EID: 69549105757     PISSN: 01605682     EISSN: 14769360     Source Type: Journal    
DOI: 10.1057/jors.2008.109     Document Type: Article

References (50)

1. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I and de Gramont A (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. MOSAIC trial. N Eng J Med 350(23): 2343-2351.
2. Beard SM, Holmes M, Price C and Majeed AW (2000). Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis. Ann Surg 232(6): 763-776.
3. Bowles CJA, Leicester R, Romaya C, Swarbrick E, Williams CB and Epstein O (2004). A prospective study of colonoscopy practice in the UK today: Are we adequately prepared for national colorectal cancer screening tomorrow? Gut 53: 277-283.
4. Ceglowski R, Churilov L and Wasserthiel J (2007). Combining data mining and discrete event simulation for a value-added view of a hospital emergency department. J Opns Res Soc 58: 246-254.
5. Curtis L and Netten A (2005). Unit costs of health and social care. Personal social. Services Research Unit at the University of Kent.
6. De Zwart IM, Griffioen G, Shaw MPC, Lamers CBHW and de Roos A (2001). Barium enema and endoscopy for the detection of colorectal neoplasia: Sensitivity, specificity, complications and its determinants. Clin Radiol 56: 401-409.
7. Department of Health (2000). The NHS Cancer Plan: A plan for investment, a plan for reform. http://www.dh.gov.uk/en/ Publicationsandstatistics/ Publications/PublicationsPolicyAndGuida nce/DH4009609 (accessed 15 June 2006).
8. Department of Health (2006a). Hospital episode statistics. http://www. dh.gov.uk/en/Publicationsandstatistics/Statistics/StatisticalWork Areas/Statisticalworkareaneighbourhood/DH4116710 (accessed 15 June 2006).
9. Department of Health (2006b). NHS reference costs 2005. http://www. dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPol icyAndGuidance/DH4133221 (accessed 15 June 2006).
10. Department of Health (2007). Cancer reform strategy. Guidance document for health and social care professionals.
11. Dinning JP, Hixson LJ and Clark LC (1994). Prevalence of distal colonic neoplasia associated with proximal colon cancers. Arch Int Med 154: 853-856.
12. Dunne JR, Gannon CJ, Osborn TM, Taylor MD, Malone DL and Napolitano LM (2002). Preoperative anemia in colon cancer: Assessment of risk factors. Am Surgeon 68(6): 582-587.
13. Felli JC and Hazen GB (1999). A Bayesian approach to sensitivity analysis. Health Econ 8: 263-268.
14. Fletcher A, Halsall D, Huxham S and Worthington D (2007). The DH Accident and Emergency Department Model: A national generic model used locally. J Opl Res Soc 58: 1554-1562.
15. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN and Parks RW (2006). Guidelines for resection of colorectal cancer liver metastases. Gut 55(3): iii1-iii8. (Pubitemid 44085662)
16. Garthwaite PH, Chilcott JB, Jenkinson DJ and Tappenden P (2008). Use of expert knowledge in evaluating costs and benefits of alternative service provisions: A case study. Int J Technol Assess Health Care 24(3): 350-357.
17. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR and Neugut AI (2003). Risk of perforation after colonoscopy and sigmoidoscopy: A population-based study. J Natl Cancer Inst 95(3): 230-236.
18. Government Actuary's Department (2007). Interim life tables http://www.gad.gov.uk/Demography%20Data/Life%20Tables/ Interimlifetables.html (accessed 15 June 2006).
19. Heald RJ, Chir M, Smedh RK, Kald A, Sexton R and Moran BJ (1997). Abdominoperineal excision of the rectum-an endangered operation. Dis Colon Rectum 40(7): 747-751.
20. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A (2008). Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: Systematic review and economic evaluation (review of Guidance No. 33). Health Technol Assess 12(15).
21. Lloyd-Jones M, Hummel S, Bansback N and Orr B (2001). A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 5(25).
22. Katsaliaki K and Brailsford S (2006). Using simulation to improve the blood supply chain. J Opns Res Soc 58: 219-227.
23. Mawdsley S, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M, Ashford R, Harrison RA, Osborne M, Livingstone JI, MacDonald P, Mitchell IC, Meyrick-Thomas J, Northover JM, Windsor A, Novell R and Wallace M (2005). Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol*Biol*Phys 63(3): 745-752.
24. Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L and Grant A (2006). Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: Systematic reviews and economic evaluation. Health Technol Assess 10(45).
25. O'Hagan A, Buck C, Daneshkhah A, Eiser R, Garthwaite P, Jenkinson D, Oakley J and Rakow T (2006). Uncertain Judgements: Eliciting Experts' Probabilities. John Wiley & Sons: New York.
26. Office for National Statistics (2007). Cancer registration statistics England 2005. http://www.statistics.gov.uk/ (accessed 15 December 2007).
27. Osman HS, Rashid N, Sathananthan N and Parker MC (2000). The cost effectiveness of self-expanding metal stents in the management of malignant left-sided large bowel obstruction. Colorectal Dis 2: 233-237.
28. Pandor A, Eggington S, Paisley S, Tappenden P and Sutcliffe P (2006). The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: Systematic review and economic evaluation. Health Technol Assess 10(41): 1-185.
29. Pidd M (2004). Computer Simulation in Management Science, 5th edn, John Wiley & Sons: New York.
30. Pilgrim H and Chilcott J (2008). Assessment of a 7-day turn-around for the reporting of cervical smear results using discrete event simulation. J Opl Res Soc 59: 902-910.
31. Pinson CW, Wright JK, Chapman WC, Garrard CL, Blair TK and Sawyers JL (1996). Repeat hepatic surgery for colorectal cancer metastasis to the liver. Ann Surg 223(6): 765-776.
32. Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A and Urban N (2000). Quality of life in survivors of colorectal carcinoma. Cancer 88(6): 1294-1303.
33. Renehan AG, O'Dwyer ST and Whynes DK (2004). Cost effectiveness analysis of intensive versus conventional follow-up after curative resection for colorectal cancer. Br Med J 328(7431): 81-85.
34. Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S and Buckley J (1997). Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 112: 17-23.
35. Rosen R, Smith A and Harrison A (2006). Future Trends and Challenges for Cancer Services in England: A Review of Literature and Policy. King's fund: London.
36. Sebag-Montefiore D, Steele R, Quirke P, Grieve R, Khanna S, Monson J, Holliday A, Thompson L, Griffiths G and Stephens R (2006). Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. ASCO Annual Meeting.
37. Seymour MT (2004). Optimizing the use and sequencing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer (ACRC): The UK MRC FOCUS. (CR08) Trial. Euro Soc Med Oncol, Conference Presentation.
38. Stevenson M, Brazier J, Calvert N, Lloyd-Jones M, Oakley J and Kanis J (2005). Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. J Opl Res Soc 56: 214-221.
39. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H and Karnon J (2006). Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56: 677-684.
40. Tappenden, P, Chilcott, JB, Brennan A, Pilgrim H (2008). Modelling the bigger picture: Using service-level modelling to support consistent resource allocation decisions across whole disease areas. Health Technology Assessment International (HTAi) Fifth Annual Meeting, 8 July 2008; Montreal, Canada.
41. Targownik LE, Spiegel BM, Sack J, Hines OJ, Dulai GS, Gralnek IM and Farrell JJ (2004) Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: A decision analysis. Gastrointest Endosc 60: 865-874.
42. Tekkis PP, Smith JJ, Constantinides V, Thompson MR, Stamatakis JD (2005). Report of the National Bowel Cancer Audit Project 'Knowing your results'.
43. The Clinical Outcomes of Surgical Therapy Study Group (2006). A comparison of laparoscopically assisted and open colectomy for colon cancer: COST trial. N Eng J Med 350(20): 2050-2059.
44. Trueman P, Chilcott J, Lowson K, Tappenden P, Bending M, Pilgrim H, Ganderton M, Chaplin S, Wright D, Shorthouse A, Duffy S, Tappenden J, Saxby R (2007a). Bowel cancer services: Costs and benefits. Summary report to the Department of Health.
45. Trueman P, Lowson K, Bending M, Ganderton M, Saxby R, Lowson P, Whitehead S, Duffy S (2007b). Bowel cancer services: Costs and benefits. Lit Rev. Report to the Department of Health.
46. Turnbull RB, Kyle K, Watson FR and Spratt J (1967). Cancer of the colon: The influence of the no touch isolation technique on survival rates. Ann Surg 166: 427.
47. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J and Scheithauer W (2005). Capecitabine as adjuvant treatment for stage III colon cancer: X-ACT trial. N Eng J Med 352(26): 2696-2704.
48. Ward S, Kaltenthaler E, Cowan J and Brewer N (2003). Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: Systematic review and economic evaluation. Health Technol Assess 7(32).
49. Weinstein MC and Stason WB (1977). Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716-721.
50. Whynes DK (2004). Cost-effectiveness of screening for colorectal cancer: Evidence from the Nottingham faecal occult blood trial. J Med Screen 11(1): 11-15.